The populations of industrialized nations are becoming steadilymore overweight as a result of changes in physical activityand diet. In recent years, concern about health and appearancehas led ever-increasing numbers of people to use a wide varietyof diets, dietary aids, and exercise regimens to lose weight.In this regard, the prospects of successfully losing weightwith the help of appetite-suppressant medication appeared toimprove with the publication in 1992 of reports showing theefficacy of fenfluramine and phentermine in combination1,2 andin 1996 with the approval by the Food and Drug Administration(FDA) of dexfenfluramine, the d-. . . [Full Text of this Article]
References
Related Letters:
Appetite-Suppressant Drugs and Valvular Heart Disease
Williamson D. F., Yanovski S. Z., Myers M. D., Moye L. A., Annegers J. F., Paoletti C. F., Shapiro S., Khan M. A., St. Peter J. V., Herzog C. A., Jick H., Weissman N. J., Gottdiener J. S., Gwynne J. T., Devereux R. B., Cannistra L. B., Cannistra A. J.
Extract |
Full Text
N Engl J Med 1999;
340:476-480, Feb 11, 1999.
Correspondence
This article has been cited by other articles:
Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., Al-Shamma, H., Smith, B., Chalmers, D., Behan, D.
(2008). Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization. J. Pharmacol. Exp. Ther.
325: 577-587
[Abstract][Full Text]
Borer, J. S., Pouleur, H., Abadie, E., Follath, F., Wittes, J., Pfeffer, M. A., Pitt, B., Zannad, F.
(2007). Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J
28: 1904-1909
[Abstract][Full Text]
Roth, B. L.
(2007). Drugs and Valvular Heart Disease. NEJM
356: 6-9
[Full Text]
Boulos, A., Rolain, J.-M., Raoult, D.
(2004). Antibiotic Susceptibility of Tropheryma whipplei in MRC5 Cells. Antimicrob. Agents Chemother.
48: 747-752
[Abstract][Full Text]
Unger, P., Nortier, J., Muniz Martinez, M.-C., Plein, D., Vandenbossche, J.-L., Vereerstraeten, P., Vanherweghem, J.-L.
(2003). High prevalence of fenfluramine-related aortic regurgitation in women with end-stage renal disease secondary to Chinese herb nephropathy. Nephrol Dial Transplant
18: 906-910
[Abstract][Full Text]
Penson, R. T., Castro, C. M., Seiden, M. V., Chabner, B. A., Lynch, T. J. Jr.
(2001). Complementary, Alternative, Integrative, or Unconventional Medicine?. The Oncologist
6: 463-473
[Abstract][Full Text]
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., Roth, B. L.
(2000). Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications. Circulation
102: 2836-2841
[Abstract][Full Text]
Tellier, P.
(1999). Aminorex to Fen/Phen: An Epidemic Foretold. Circulation
100
: e146-e146
[Full Text]
Biswas, S. S., Donovan, C. L., Forbess, J. M., Royal, S. H., Landolfo, K. P.
(1999). Valve replacement for appetite suppressant-induced valvular heart disease. Ann. Thorac. Surg.
67: 1819-1822
[Abstract][Full Text]
Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., Thompson, L. J.
(1999). The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?. JAMA
281: 1728-1734
[Abstract][Full Text]
Williamson, D. F., Yanovski, S. Z., Myers, M. D., Moye, L. A., Annegers, J. F., Paoletti, C. F., Shapiro, S., Khan, M. A., St. Peter, J. V., Herzog, C. A., Jick, H., Weissman, N. J., Gottdiener, J. S., Gwynne, J. T., Devereux, R. B., Cannistra, L. B., Cannistra, A. J.
(1999). Appetite-Suppressant Drugs and Valvular Heart Disease. NEJM
340: 476-480
[Full Text]